Left Behind? Drug Discovery in Extensive Stage Small Cell Lung Cancer

Por Riess, Jonathan W., Lara, Primo N.
Publicado em 2014

Toward a Common Therapeutic Framework in Castration Resistant Prostate Cancer: A Model for Urologic Oncology and Medical Oncology Interaction

Por de Vere White, Ralph, Lara, Primo N.
Publicado no Urol Oncol (2014)

NEW AND EMERGING DEVELOPMENTS IN EXTENSIVE STAGE SMALL CELL LUNG CANCER THERAPEUTICS

Por Parikh, Mamta, Riess, Jonathan, Lara, Primo N.
Publicado no Curr Opin Oncol (2016)

Progress in Personalizing Chemotherapy for Bladder Cancer

Por Chang, James S., Lara, Primo N., Pan, Chong-Xian
Publicado em 2012

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

Por Semrad, Thomas J., Gandara, David R., Lara, Primo N.
Publicado em 2011

Twenty Years Post-NIH Revitalization Act: Renewing the Case for Enhancing Minority Participation in Cancer Clinical Trials

Por Chen, Moon S., Lara, Primo N., Dang, Julie H.T., Paterniti, Debora A., Kelly, Karen
Publicado em 2014

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

Por Semrad, Thomas J., Eddings, Courtney, Dutia, Mrinal P., Christensen, Scott, Lara, Primo N.
Publicado em 2013

PREDICTORS OF SURVIVAL IN ADVANCED RENAL CELL CARCINOMA: LONG-TERM RESULTS FROM SOUTHWEST ONCOLOGY GROUP TRIAL S8949

Por Lara, Primo N., Tangen, Catherine M., Conlon, Sarah, Flanigan, Robert C., Crawford, E. David
Publicado em 2008

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

Por Holland, William S., Chinn, Danielle C., Lara, Primo N., Gandara, David R., Mack, Philip C.
Publicado no J Cancer Res Clin Oncol (2014)

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

Por Gandara, David R., Hammerman, Peter S., Sos, Martin L., Lara, Primo N., Hirsch, Fred R.
Publicado no Clin Cancer Res (2015)

Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour

Por Pugashetti, Neil, Yap, Stanley A., Lara, Primo N., Gandour-Edwards, Regina, Dall’Era, Marc A.
Publicado no Can Urol Assoc J (2015)

Feasibility Study of Intra-patient Sorafenib Dose-Escalation or Re-Escalation in Patients with Previously Treated Advanced Solid Tumors

Por Semrad, Thomas J., Eddings, Courtney, Pan, Chong-Xian, Lau, Derick H., Gandara, David, Beckett, Laurel, Lara, Primo N.
Publicado em 2011

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells

Por Wang, Sisi, Zhang, Hongyong, Malfatti, Michael, de Vere White, Ralph, Lara, Primo N., Turteltaub, Kenneth, Henderson, Paul, Pan, Chong-xian
Publicado em 2010

Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients

Por Lo, Ernest N., Beckett, Laurel A., Pan, Chong-Xian, Robles, Daniel, Suga, Jennifer M., Sands, Jacob M., Lara, Primo N.
Publicado no Prostate Cancer Prostatic Dis (2015)

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy

Por Holland, William S., Tepper, Clifford G., Pietri, Jose E., Chinn, Danielle C., Gandara, David R., Mack, Philip C., Lara, Primo N.
Publicado no Cancer Chemother Pharmacol (2011)

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group study (S0339)

Por Davies, Angela M., Chansky, Kari, Lara, Primo N., Gumerlock, Paul H., Crowley, John, Albain, Kathy S., Vogel, Stanley J., Gandara, David R.
Publicado em 2009

Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer

Por Chen, Gigi, Huynh, Minh, Fehrenbacher, Lou, West, Howard, Lara, Primo N., Yavorkovsky, Leonid L., Russin, Michael, Goldstein, Desiree, Gandara, David, Lau, Derick
Publicado em 2009

Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Por Twardowski, Przemyslaw, Stadler, Walter M, Frankel, Paul, Lara, Primo N, Ruel, Christopher, Chatta, Gurkamal, Heath, Elisabeth, Quinn, David I, Gandara, David R
Publicado em 2010

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium Study

Por Lara, Primo N., Longmate, Jeff, Evans, Christopher P., Quinn, David I., Twardowski, Przemyslaw, Chatta, Gurkamal, Posadas, Edwin, Stadler, Walter, Gandara, David R.
Publicado em 2009

Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity

Por Gandara, David R., Li, Tianhong, Lara, Primo N., Mack, Philip C., Kelly, Karen, Miyamoto, Suzanne, Goodwin, Neal, Beckett, Laurel, Redman, Mary W.
Publicado em 2012